News

The company shared results from the AAVB-081 clinical program and AAVB-039 preclinical program at ARVO.

The biomarkers are especially crucial for patients with lupus nephritis.

Post hoc analysis of GATHER1 and GATHER2 showed that reduced EZ-RPE central subfield thickness is a strong predictor of greater future vision loss.

Boehringer Ingelheim announced that the phase 2 clinical studies will investigate a potential first-in-class oral compound and a highly specific antibody fragment for geographic atrophy.

At Retina World Congress 2025, Dilsher S. Dhoot, MD, shares updates on the HELIOS trial and the potential future of tyrosine kinase inhibitors (TKIs).

Topline results from the Magnify phase 2 clinical trial of oral zervimesine show 28.6% slower geographic atrophy lesion growth compared with placebo.

Machine learning algorithms enhance retinopathy of prematurity screening using smartphone images, expanding access in low-resource settings and easing pediatric ophthalmologist workloads.

The recombinant human vascular endothelial growth factor receptor (VEGFR)-antibody human complement receptor 1 (CR1) fusion protein will be intravitreally administered in up to 150 patients.

According to Dr. Danzig, the DIAMOND trial demonstrates efficacy of OCS-01, a topical drop, in patients with diabetic macular edema.

Topcon Healthcare launches IDHea, an innovative platform enhancing AI research and ocular data access to improve clinical outcomes in healthcare.

The trial assesses GAL-101 as an oral therapy designed to treat Alzheimer disease, dry age-related macular degeneration, and glaucoma.

The phase 2 clinical trial data evaluating the efficacy, safety, and dosing intervals of high-dose IBI302 were presented during the annual 2025 ARVO meeting.

Jennifer Lim, MD, FARVO, FASRS, discusses her ARVO presentation on sickle cell retinopathy, highlighting improvements in retinal surgery techniques and instrumentation.

New research reveals subretinal drusenoid deposits as potential indicators of serious heart disease, highlighting the need for ophthalmologists to screen patients effectively.

Opus Genetics reveals promising 1-year results from OPGx-LCA5 gene therapy, showing sustained vision improvements in adults with LCA5 retinal degeneration.

The preclinical data was presented during the 2025 ARVO meeting.

The PRISM clinical trial assesses 4D-150 (4D Molecular Therapeutics) in adults with neovascular age-related macular degeneration, also known as wet AMD.

In an analysis of the IRIS database, investigators assessed almost 1,200 eyes that had been treated with faricimab.

The LUMEOS phase 3 clinical trial resulted in botaretigene sparoparvovec not meeting primary endpoints to improve visual navigation of XLRP.

KIO-104 is a therapeutic candidate shown to significantly reduce retinal scar formation.

The VAN-2401 phase 1 clinical trial will evaluate the use of KH658 for the treatment of wet AMD.

4D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) to be targeted to the retina with a single, well-tolerated intravitreal injection.

Lukas Scheibler, PhD, and Graham Cooper join Tavo Biotherapeutics and chief research and development officer and chief financial officer.